Ocera Therapeutics Inc.
http://www.ocerainc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ocera Therapeutics Inc.
Zydus MD On Pipeline-In-A-Drug Approach, Partnering Intent
Zydus MD Sharvil Patel talks to Scrip about a pipeline-in-a-drug approach for novel molecules like ZYIL-1, the intent behind deals with Daewoong and LiqMeds and expected timelines for trial readouts of its PBC/NASH candidate saroglitazar
Zydus On Acquisitions, $100m Specialty Biz Target, Asacol Competition
Zydus is still on the lookout for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of generic Revlimid sales in Q2 led to a 24% drop over the previous quarter.
Zydus On Acquisitions, $100m Specialty Biz Target, gAsacol Competition
Zydus is still on the look out for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of Revlimid sales in Q2 led to a 24% drop over the previous quarter.
After Floating To Butterfly Network, CEO DeVivo Is Ready To Sting Like A Bee
He may not be Ali, but Butterfly Network's new CEO, Joseph DeVivo, believes Butterly’s microchip tech packs a formidable punch. He expects the company’s technology will help it transcend the market-development challenges the company faced under its previous leaderships.
Company Information
- Other Names / Subsidiaries
-
- Tranzyme Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice